GILD US3755581036

Report

Delayed Nasdaq - 12/03 04:00:00 pm
69.56	USD		-0.16%

12/04	Gilead recalls vials of COVID-19 drug remdesivir due to glass contamination	AQ
12/03	Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK)	AQ
12/02	DOJ, SEC Charge Former Immunomedics Finance Chief With Insider Trading	DJ

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

11/29/2021	11/30/2021	12/01/2021	12/02/2021	12/03/2021	Date
70.65(c)	68.93(c)	68.93(c)	69.67(c)	69.56(c)	Last
8 902 529	15 465 600	8 518 463	9 411 737	7 724 167	Volume
+0.54%	-2.43%	0.00%	+1.07%	-0.16%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021	26 515 M - -
Net income 2021	7 187 M - -
Net Debt 2021	22 390 M - -
P/E ratio 2021	12,1x
Yield 2021	4,07%

Sales 2022	24 071 M - -
Net income 2022	6 360 M - -
Net Debt 2022	17 055 M - -
P/E ratio 2022	13,9x
Yield 2022	4,28%

Capitalization	87 255 M 87 255 M -
EV / Sales 2021	4,14x
EV / Sales 2022	4,33x
Nbr of Employees	13 600
Free-Float	99,9%

More Financials

Company

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular...

Sector

Biotechnology & Medical Research

Calendar

12/07 | 08:00am

Presentation

More about the company

Ratings of Gilead Sciences, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

B-

More Ratings

All news about GILEAD SCIENCES, INC.

12/04	Gilead recalls vials of COVID-19 drug remdesivir due to glass contamination	AQ
12/03	Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..	AQ
12/02	DOJ, SEC Charge Former Immunomedics Finance Chief With Insider Trading	DJ
12/02	What COVID-19 vaccine and drug makers have to say about Omicron	RE
12/01	GILEAD SCIENCES : Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant	PU
11/30	NRX Pharmaceuticals Shares Slide 16% After Soaring on COVID-19 Drug, Vaccine Updates	MT
11/30	Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..	MT
11/30	Regeneron's COVID-19 antibody drug may be less effective against Omicron	RE
11/30	Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..	AQ
11/29	NRX Pharmaceuticals Soars After Saying Zyesami Outperformed Remdesivir for Critical COV..	MT
11/29	Gilead Sciences Selects Amazon Web Services as Cloud Provider	MT
11/29	Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..	BU
11/24	Gilead Sciences' Trodelvy (sacituzumab govitecan) Granted European Commission Marketing..	AQ
11/24	Gilead Sciences, Merck Pause Phase 2 HIV Trial	MT
11/23	Gilead Sciences' Trodelvy Gets Marketing Authorization from European Commission	MT

More news

News in other languages on GILEAD SCIENCES, INC.

12/03	INTESA SANPAOLO : premia migliore startup innovativa a Pni 2021
12/02	STARTUP : 16 i progetti finalisti per Pni 2021
11/30	Les actions de NRX Pharmaceuticals chutent de 16% après avoir grimpé en flèche grâce au..
11/30	Selon Oppenheimer, les noms pharmaceutiques connaîtront une volatilité accrue en fin d'..
11/29	NRX Pharmaceuticals s'envole après avoir déclaré que le Zyesami a surpassé le Remdesivi..

More news

Analyst Recommendations on GILEAD SCIENCES, INC.

11/19	Wedbush Lifts Price Target on Arcus Biosciences to $67 From $52 After Gilead Opts In to..	MT
11/18	Piper Sandler Initiates Coverage of Gilead Sciences With Neutral Rating, $77 Price Targ..	MT
11/18	BMO Upgrades Gilead Sciences to Outperform From Market Perform, Sets $85 Price Target	MT

More recommendations

Provided by Scoopnest.com

Analysis

Marketmind: The ECB's inflation conundrum